NeurologyLive® Friday 5 — July 12, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, June 2024: Approvals, Designation, and Clearance

The FDA was busy in June 2024, making a number of decisions on potential new therapeutic agents including granting approvals, a designation, a clearance, an acceptance of application, a recommendation, and issuing a complete response letter.

2: NeurologyLive® Clinician of the Month Spotlight: Marisa McGinley, DO

As part of our monthly clinician spotlight, NeurologyLive® highlighted multiple sclerosis expert Marisa McGinley, DO, the staff neurologist at Cleveland Clinic’s Mellen Center for MS.

3: The Unexpected Maestro: How AI Is Composing a New Future for Dementia Care

Neal K. Shah, CEO of CareYaya Health Technologies, discussed the groundbreaking potential of AI-powered music therapy in revolutionizing dementia care, offering personalized interventions that can improve quality of life.

4: NeuroVoices: Kelly Papesh, DNP, APRN, FNP-BC, on Understanding Patient Silence for Movement Disorder Concerns in the Clinical Setting

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.

5: Broad FDA Approval of Gene Therapy Expands Treatment Choices for Duchenne Muscular Dystrophy: Debra Miller & Michael Kelly, PhD

The chief executive officer and the chief scientific officer at CureDuchenne talked about a recent webinar that discussed the broad FDA approval of a gene therapy for Duchenne muscular dystrophy, highlighting patient choice and the ongoing efforts to improve treatments. [WATCH TIME: 9 minutes]